NCT02674295View on ClinicalTrials.gov

A Mass Balance Study With a Microtracer Dose of 14C-esketamine in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Healthy
Interventions
DRUG

Esketamine 50 mg

50 mg of oral esketamine, fortified with a microtracer dose of 14C-esketamine, as an aqueous solution mixed with apple juice for administration (80 mL total volume)

DRUG

Esketamine 20 mg

20 mg of intravenous esketamine in 30 mL, fortified with a microtracer dose of 14C-esketamine, as a 30-minute intravenous infusion.

Trial Locations (1)

Unknown

Madison

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02674295 - A Mass Balance Study With a Microtracer Dose of 14C-esketamine in Healthy Male Participants | Biotech Hunter | Biotech Hunter